RedHill Biopharma Ltd. has announced a significant milestone in its clinical development efforts. The company has secured a $2.9 million grant from the National Cancer Institute (NCI) to support clinical trials exploring the effectiveness of its drug Opaganib in combination with CAR T-cell therapy for ultra-high-risk multiple myeloma patients.
This funding is intended to cover the costs of two phases of clinical trials. The first phase will evaluate the safety of the treatment combination and determine the appropriate dosage of Opaganib, while the second phase aims to gather preliminary evidence of its effectiveness.
Background
RedHill Biopharma Ltd. is a specialty biopharmaceutical company based in Tel Aviv, Israel, focused on developing and commercializing proprietary drugs for gastrointestinal diseases, infectious diseases, and oncology. The company trades on the Nasdaq under the ticker RDHL. Its recent filings include a series of 6-K forms, with the latest filed on October 19, 2026.
What the Filing Says
The filing confirms that the $2.9 million grant will fund clinical trials conducted in partnership with the University of Oklahoma, which is expected to enroll up to 39 patients across two trial phases. The trials will assess the safety and effectiveness of Opaganib when used in conjunction with CAR T-cell therapy.
Impact
This development may significantly impact patients suffering from ultra-high-risk multiple myeloma, a condition that often returns despite existing treatment options. The combination therapy could offer a new avenue for improving patient outcomes in a challenging treatment landscape.
What's Next
The filing does not specify what happens next, but the initiation of the clinical trials is expected to follow the grant's allocation.